People: Proteome Sciences PLC (PRM.L)

PRM.L on London Stock Exchange

67.00GBp
20 May 2013
Price Change (% chg)

-0.25p (-0.37%)
Prev Close
66.75p
Open
--
Day's High
--
Day's Low
--
Volume
115,748
Avg. Vol
333,248
52-wk High
74.00p
52-wk Low
24.00p

Search Stocks

Summary

Name Age Since Current Position

R. Harris

 Non-Executive Chairman of the Board

Christopher Pearce

 Chief Executive, Executive Director

James Malthouse

 Finance Director, Company Secretary, Executive Director

Ian Pike

 2010 Chief Operating Officer, Executive Director

Malcolm Ward

 2011 Chief Technical Officer - London Research Facility

Hans-Dieter Zucht

 2011 Chief Technical Officer - Proteome Sciences R&D, Frankfurt

Glenn Barney

 2011 Vice President - Business Development, USA

Josef Schwarz

 2011 Head - Projects & Production, Proteome Sciences R&D

Rainer Voegeli

 2011 Commercial Director, Europe

William Dawson

 Non-Executive Director

Anthony Walker

 50 2010 Non-Executive Director
» Insider Trading

Biographies

Name Description

R. Harris

 Mr. R. S. Harris is Non-Executive Chairman of the Board of Proteome Science PLC. Steve Harris is a Fellow of the Royal Pharmaceutical Society. Until June 1995 he was Director of Development and Licensing at Medeva plc. He has worked in the pharmaceutical industry for 45 years including with ICI, Merck Sharp & Dohme, Eli Lilly, Boots, Reckitt and Colman, and Gensia. He is non-executive Director of Advanced Medical Solutions plc and Phynova plc and is non-executive Chairman of Cyprotex plc, Aquapharm Biodiscovery Ltd and Ocelus Ltd.

Christopher Pearce

 Mr. Christopher D.J. Pearce is Chief Executive, Executive Director of Proteome Science PLC. Christopher Pearce has built the Group since inception and has been responsible for the formulation and implementation of strategy, collaborative and licensing agreements, and intellectual property. He was co-founder and Executive Chairman of Fitness First plc, the international fitness chain.

James Malthouse

 Mr. James L. Malthouse is Finance Director, Company Secretary, Executive Director of Proteome Science PLC. James Malthouse joined the Group in 1993 and is a Chartered Accountant with banking and corporate finance experience. He was Chairman and Finance Director of Unigroup plc and Finance Director of Harcourt Group plc.

Ian Pike

 Dr. Ian H. Pike is Chief Operating Officer, Executive Director of Proteome Sciences PLC. Ian Pike has over 20 years’ experience working in the diagnostics and biotechnology sectors. Having gained a PhD in Medical Microbiology, he joined Wellcome Diagnostics as a research group leader and spent eight years working on new diagnostic assays, particularly for hepatitis. In December 1999, he joined the Technology Transfer Office of the UK Medical Research Council with responsibility for patents and commercialisation of a wide portfolio of technologies related to the biomedical sector. Most recently, Ian worked for Cancer Research Ventures managing intellectual property and performing business development activities in Europe and the USA.

Malcolm Ward

 Dr. Malcolm Ward is Chief Technical Officer - London Research Facility of Proteome Sciences PLC. Malcolm Ward joined Proteome Sciences plc in May 2001 having previously worked for GlaxoWellcome for 12 years, in protein mass spectrometry. He was involved in the establishment of the new edge protein separation and mass spectrometry facility at the Institute of Psychiatry, King’s College London. His research team is involved in biomarker discovery, validation and assay development. His academic qualifications include a Master of Science (MSc) in Molecular Biology from the University of Hertfordshire in 1996 and a Graduateship from the Royal Society of Chemistry (GRSC) in 1992. He obtained a PhD in Applied Proteomics at King’s College, London in 2009.

Hans-Dieter Zucht

 Dr. Hans-Dieter Zucht is Chief Technical Officer - Proteome Sciences R&D, Frankfurt of Proteome Sciences PLC. Dr. Zucht came to Proteome Sciences in November 2008. He was Chief Technology Officer and Head of Bioinformatics at Biovision AG (Digilab Biovision GmbH) in Germany for 10 years. A biochemist by training, he worked from 1992 in molecular biology and peptide biochemistry at the Lower Saxony Institute of Peptide Research (later IPF pharmaceuticals) in Hanover, Germany. He is visiting professor at the Paris Lodron University in Salzburg, Austria.

Glenn Barney

 Mr. Glenn Barney is Vice President - Business Development, USA of Proteome Sciences PLC. Glenn brings over 25 years of sales and business development experience with global life sciences companies, with biomarker focus. He was formerly VP Business Development at NextGen Sciences Inc. and held senior positions at Decision Biomarkers and Parkin Elmer Inc. Mr. Barney holds a BA in Biology from Boston University.

Josef Schwarz

 Dr. Josef Schwarz is Head - Projects & Production, Proteome Sciences R&D of Proteome Sciences PLC. Joseph Schwarz joined the Group in summer 2002 when Xzillion, the former proteomics division of Aventis Research and Technologies, was acquired by Proteome Sciences plc. He worked for Aventis/Hoechst Research and Technologies for 6 years, initially as head of mass spectrometry and later as research collaboration project leader. He was instrumental in the establishment of the integrated high throughput 2DE/mass spectrometry proteomics platform at the Frankfurt research facility. Josef Schwarz holds a PhD in organic chemistry/mass spectrometry from the Technical University of Berlin, Germany and a MBA from the University of Durham, UK. He is an author of a number of publications and co-inventor of patents.

Rainer Voegeli

 Dr. Rainer Voegeli is Commercial Director, Europe of Proteome Sciences PLC. Dr. Rainer Voegeli joined Proteome Sciences in September 2007 after being Head of Business Development at BioVisioN AG (later Digilab BioVisioN GmbH) where he concluded deals with many pharmaceutical companies. Before moving into Biotechnology, he worked for ASTA Medica AG in research and business development positions in Germany and the USA. Rainer Voegeli qualified with a PhD in biochemistry at the University of Giessen, Germany and has developed considerable proteomics in peptides and proteins.

William Dawson

 Professor William Dawson is Non-Executive Director of Proteome Science PLC. Professor William Dawson retired from Eli Lilly and Company in August 1996 after 27 years’ service, 14 as Research Director in the UK and latterly as Director of Technology Acquisition, Europe. He is a Director of Bionet Ltd, Pharmovation Ltd, Novolytics Ltd, Antitope Ltd and a Fellow of the Royal Pharmaceutical Society and of the Royal Society of Chemistry.

Anthony Walker

 Dr. Anthony Ian Walker has been Non-Executive Director of Proteome Sciences PLC. Dr. Anthony Walker has considerable commercial and scientific experience in the life sciences and biotechnology industries with 12 years as CEO of Onyvax, a cancer vaccines company he co-founded in 1997, and currently as a partner of Alacrita LLP. He spent 10 years as a management consultant specialising in the pharmaceutical and biotechnology industries initially at Arthur D. Little where he launched the UK Pharmaceutical Practice and subsequently at Wilkerson Group.

Basic Compensation

Name Fiscal Year Total

R. Harris

 38,000

Christopher Pearce

 262,939

James Malthouse

 149,684

Ian Pike

 196,680

Malcolm Ward

 --

Hans-Dieter Zucht

 --

Glenn Barney

 --

Josef Schwarz

 --

Rainer Voegeli

 --

William Dawson

 --

Anthony Walker

 --
As Of 30 Dec 2011

Insider Trading

» Full list on Insider Trading
Search Stocks